Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Papp

Showing results (251-260 of 461) with videos related to

Pageof 47
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|August 11, 2021
Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE studyW Gulliver, A Alavi, M C Wiseman, et al.
The British Journal of Dermatology|January 23, 2016
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasisK A Papp, M A Menter, M Raman, et al.
The British Journal of Dermatology|November 29, 2018
Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studiesK Reich, K A Papp, A W Armstrong, et al.
The British Journal of Dermatology|March 1, 2018
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3K A Papp, K B Gordon, R G Langley, et al.
The British Journal of Dermatology|February 24, 2012
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 yearsA B Kimball, K B Gordon, S Fakharzadeh, et al.
Journal of Cutaneous Medicine and Surgery|March 24, 2022
Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With AdalimumabWayne Gulliver, Afsaneh Alavi, Marni C Wiseman, et al.
The Journal of Investigative Dermatology|January 23, 2025
Phase II Randomized Trial of BI 730357, an Oral RORγt Inhibitor, for Moderate-to-Severe Plaque PsoriasisMelinda J Gooderham, Ulrich Mrowietz, Werner Kadus, et al.
The American Journal of Psychiatry|April 1, 1994
Anxiogenic effects of CO2 and hyperventilation in patients with panic disorderJ M Gorman, L A Papp, J D Coplan, et al.
Journal of the American Academy of Dermatology|March 22, 2001
Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort studyV C Ho, C E Griffiths, J Berth-Jones, et al.
Journal of the American Academy of Dermatology|March 19, 2011
Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label studyBruce E Strober, Yves Poulin, Francisco A Kerdel, et al.
Pageof 47

Showing results (251-260 of 461) with videos related to

Sort By:
Pageof 47
Journal of the European Academy of Dermatology and Venereology : JEADV|August 11, 2021
Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE studyW Gulliver, A Alavi, M C Wiseman, et al.
The British Journal of Dermatology|January 23, 2016
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasisK A Papp, M A Menter, M Raman, et al.
The British Journal of Dermatology|November 29, 2018
Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studiesK Reich, K A Papp, A W Armstrong, et al.
The British Journal of Dermatology|March 1, 2018
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3K A Papp, K B Gordon, R G Langley, et al.
The British Journal of Dermatology|February 24, 2012
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 yearsA B Kimball, K B Gordon, S Fakharzadeh, et al.
Journal of Cutaneous Medicine and Surgery|March 24, 2022
Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With AdalimumabWayne Gulliver, Afsaneh Alavi, Marni C Wiseman, et al.
The Journal of Investigative Dermatology|January 23, 2025
Phase II Randomized Trial of BI 730357, an Oral RORγt Inhibitor, for Moderate-to-Severe Plaque PsoriasisMelinda J Gooderham, Ulrich Mrowietz, Werner Kadus, et al.
The American Journal of Psychiatry|April 1, 1994
Anxiogenic effects of CO2 and hyperventilation in patients with panic disorderJ M Gorman, L A Papp, J D Coplan, et al.
Journal of the American Academy of Dermatology|March 22, 2001
Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort studyV C Ho, C E Griffiths, J Berth-Jones, et al.
Journal of the American Academy of Dermatology|March 19, 2011
Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label studyBruce E Strober, Yves Poulin, Francisco A Kerdel, et al.
Pageof 47